索拉非尼联合阿霉素经肝动脉化疗栓塞治疗晚期肝癌临床观察

Clinical Observation of Sorafenib Combined with Adriamycin Transcatheter Arterial Chemoembolization to Treat Advanced Hepatocellular Carcinoma

目的观察索拉非尼联合阿霉素经肝动脉化疗栓塞(TACE)治疗晚期肝细胞肝癌(HCC)的临床疗效和毒性反应。方法选取病理证实符合观察标准且获随访的晚期HCC患者18例,治疗过程中每4～6周评价疗效和毒性反应,并随访中位至疾病进展时间和中位总生存期。结果随访时间内索拉非尼联合阿霉素TACE治疗的晚期HCC患者中位至疾病进展时间6.1个月,中位总生存期13.2个月;索拉非尼相关毒性反应主要为手足皮肤反应、腹泻、高血压和乏力,经对症处理后绝大多数得到缓解。结论索拉非尼联合阿霉素TACE治疗晚期HCC安全、有效。

Objective To investigate the therapeutic effect and adverse reaction of sorafenib combined with adriamycin transcatheter arterial chemoembolization（TACE）to treat advanced gepatocellular carcinoma（HCC）.Methods According to the test criteria,18 patients with advanced HCC who was pathologically confirmed or clinically diagnosed were visited.The therapeutic effect and adverse reaction were evaluated every 4-6 weeks,and the median time to progression and the median overall survival time were followed up in the same time.Results In the follow-up period,the median time to progression was 6.1 months,and the median overall survival time was 13.2 months.The most common adverse events were hand foot skin reaction,diarrhea,hypertension and feeble,most of them were released after treatment.Conclusions It is safe and effective to administer sorafenib combined TACE with ADM in advanced HCC.